Stockreport
Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors [MarketWatch]
Last acorda therapeutics earnings: 5/2 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations: acorda.com/investors
PDF
Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors Shares of biotech Acorda Therapeutics Inc. ACOR, +1.01% surged 20% in premarket trade Friday, after media reports that Biogen Inc. BIIB, -0.12% and others are eyeing the company as a possible takeover target. The speculation has been swirling for more than a week. On Thursday, the company offered preliminary guidance for 2017 sales of $542 million, an increase of approximately 10% from 2016. The FactSet consensus is for sales of $568 million. Chief Executive Ron Cohen said he expects 2018 to be a transformative year and for the company to achieve approval and launch its Inbrija investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson's disease taking carbidopa/levodopa. Shares have gained 21% in the last 12 months, while the S&P 500 SPX, -0.16% has gained about 24%.
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | ACOR | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ACOR alerts
ACOR alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACOR alerts
High impacting ACORDA THERAPEUTICS news events
Weekly update
A roundup of the hottest topics
ACOR
NEWS
NEWS
- Acorda Therapeutics Inc (NASDAQ: ACOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $33.00 price target on the stock.[MarketBeat]
- Acorda Therapeutics Inc (NASDAQ: ACOR) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.[MarketBeat]
- Acorda Therapeutics Inc (NASDAQ: ACOR) was upgraded by analysts at TheStreet from a "d+" rating to a "c-" rating.[MarketBeat]
- Acorda Therapeutics Inc (NASDAQ: ACOR) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.[MarketBeat]
- Acorda to Present Data for INBRIJA™ (levodopa inhalation powder) at 2nd Pan American Parkinson’s Disease and Movement Disorders Congress[Business Wire]
- More
ACOR
SEC Filings
SEC Filings
- 7/10/18 - Form 4
- 7/10/18 - Form SC
- 7/5/18 - Form 4
- ACOR's page on the SEC website
- More